These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 14741069)

  • 21. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
    Päivärinta M; Tapanainen P; Veijola R
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
    J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin preparations with prolonged effect.
    Owens DR
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S5-14. PubMed ID: 21668337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes.
    Dailey G; Strange P
    Am J Manag Care; 2008 Jan; 14(1):25-30. PubMed ID: 18197742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initiation of insulin glargine in children and adolescents with type 1 diabetes.
    Tan CY; Wilson DM; Buckingham B
    Pediatr Diabetes; 2004 Jun; 5(2):80-6. PubMed ID: 15189493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
    Yokoyama H; Tada J; Kamikawa F; Kanno S; Yokota Y; Kuramitsu M
    Diabetes Res Clin Pract; 2006 Jul; 73(1):35-40. PubMed ID: 16513202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin detemir: a new basal insulin analogue.
    Soran H; Younis N
    Diabetes Obes Metab; 2006 Jan; 8(1):26-30. PubMed ID: 16367879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety.
    Rolla A
    Am J Med; 2008 Jun; 121(6 Suppl):S9-S19. PubMed ID: 18514090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K; Dornhorst A; Sreenan S
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Innovative insulins--where do analogues fit?
    Phillips LK; Phillips PJ
    Aust Fam Physician; 2006 Dec; 35(12):969-73. PubMed ID: 17149471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel insulins: expanding options in diabetes management.
    Gerich JE
    Am J Med; 2002 Sep; 113(4):308-16. PubMed ID: 12361817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetically engineered insulin analogs: diabetes in the new millenium.
    Vajo Z; Duckworth WC
    Pharmacol Rev; 2000 Mar; 52(1):1-9. PubMed ID: 10699152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
    Owens DR; Bolli GB
    Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics of basal insulins.
    Porcellati F; Bolli GB; Fanelli CG
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S15-24. PubMed ID: 21668333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.
    Edwards KL; Riche DM; Stroup JS; Goldman-Levine JD; Padiyara RS; Cross LB; Kane MP
    Pharmacotherapy; 2010 Sep; 30(9):955-65. PubMed ID: 20795850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The future of basal insulin supplementation.
    Simon AC; DeVries JH
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S103-8. PubMed ID: 21568722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin glargine: a new basal insulin.
    Levien TL; Baker DE; White JR; Campbell RK
    Ann Pharmacother; 2002 Jun; 36(6):1019-27. PubMed ID: 12022906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The past, present, and future of basal insulins.
    Pettus J; Santos Cavaiola T; Tamborlane WV; Edelman S
    Diabetes Metab Res Rev; 2016 Sep; 32(6):478-96. PubMed ID: 26509843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Basal insulin: physiology, pharmacology, and clinical implications.
    Niswender KD
    Postgrad Med; 2011 Jul; 123(4):17-26. PubMed ID: 21680985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.